



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TECHNICALLY *Speaking*

Place your order with CEDARLANE® or your local distributor.

Please contact CEDARLANE® for lot specific information.

Purified Anti-Mouse CD5 (Ly 1.1) Monoclonal Antibody - No Azide

**CL8911NA
LOT: 8121NA**

DESCRIPTION:

Cedarlane's anti-mouse CD5 (Ly 1.1) monoclonal antibody reacts with T lymphocytes from mouse strains expressing the Ly 1.1 phenotype, but does not react with lymphocytes from mouse strains expressing the Ly 1.2 phenotype. Can be used to identify T helper cells as they have a high density of Ly 1 on their surface.

PRESENTATION:

1.0 mg purified Ig buffered in PBS, no preservative. Filtered to 0.2 µm.

STORAGE/STABILITY:

Stable at 4°C. For long term storage, aliquot and freeze unused portions at -20°C in volumes appropriate for single usage. Avoid repeated freeze/thaw cycles. Handle under aseptic conditions.

For more information or to place an order please contact...

CEDARLANE®
LABORATORIES LIMITED
5516 - 8th Line, R.R.#2, Hornby, Ontario, CANADA L0P 1E0



*toll free: 1-800-268-5058
in North America*

phone: (905) 878-8891 • fax: (905) 878-7800

or visit our website for a list of our international distributors including contact information
website: www.cedarlanelabs.com • e-mail: info@cedarlanelabs.com

SPECIFICATIONS:

Clone: 7-20.6/3

Hybridoma Production:

Immunization: REC: 129/ReJ

Donor: B6-Ly-1^a

Fusion Partner: Spleen from immunized recipient fused with
*myeloma P3-NSI-Ag4-1

Specificity: Mouse CD5 (Ly 1.1)

Ig Class: Mouse IgG_{2a}

Format: Purified Ig buffered in PBS, no preservative. (Purified from ascitic fluid via Protein G Chromatography)

Antibody Concentration: 1.0 mg/ml

FLOW CYTOMETRY ANALYSIS:**Method:**

1. Prepare a cell suspension in media A. For cell preparations, deplete the red blood cell population with Lympholyte[®]-M cell separation medium (CL5030).
2. Wash 2 times.
3. Resuspend the cells to a concentration of 2×10^7 cells/ml in media A. Add 50 μ l of this suspension to each tube (each tube will then contain 1×10^6 cells, representing 1 test).
4. To each tube, add 0.2-0.5 μ g* of **CL8911NA**.
5. Vortex the tubes to ensure thorough mixing of antibody and cells.
6. Incubate the tubes for 30 minutes at 4°C.
7. Wash 2 times at 4°C.
8. Add 100 μ l of secondary antibody **CLCC30201** (FITC Goat anti-mouse IgG (H+L)) at a 1:500 dilution.
9. Incubate the tubes at 4°C for 30-60 minutes.
(It is recommended that the tubes are protected from light since most fluorochromes are light sensitive).
10. Wash 2 times at 4°C in media B.
11. Resuspend the cell pellet in 50 μ l ice cold media B.
12. Transfer to suitable tubes for flow cytometric analysis containing 15 μ l of propidium iodide at 0.5 mg/ml in PBS. This stains dead cells by intercalating in DNA.

Media:

- A. Phosphate buffered saline (pH 7.2) + 5% normal serum of host species + sodium azide (100 μ l of 2M sodium azide in 100 mls).
- B. Phosphate buffered saline (pH 7.2) + 0.5% Bovine serum albumin + sodium azide (100 μ l of 2M sodium azide in 100 mls).


Results:Tissue Distribution by Flow Cytometry Analysis:

Mouse Strain: C3H/He

Cell Concentration : 1×10^6 cells per tests

Antibody Concentration Used: $0.5 \mu\text{g}/10^6$ cells

Isotypic Control: Purified Mouse IgG_{2a}



Cell Source: Thymus

Percentage of cells stained above control: 97.9%

N.B.: Appropriate control samples should always be included in any labelling studies.

*** For optimal results in various applications, it is recommended that each investigator determine dilutions appropriate for individual use.**

CYTOTOXICITY ANALYSIS:

Method:

1. Prepare a cell suspension from the appropriate tissue in Cedarlane Cytotoxicity Medium^a or equivalent. Remove red cells and dead cells (where necessary) by purification of viable lymphocytes on Cedarlane Lympholyte[®]-M^b density cell separation medium. After washing, adjust the cell concentration to 1×10^6 cells per ml in Cytotoxicity Medium.
2. Add the antibody to a final concentration of 1:500 and mix.
3. Incubate for 60 minutes at 4°C.
4. Centrifuge to pellet the cells and discard the supernatant.
5. Resuspend to the original volume in Cedarlane Low-Tox[®]-M Rabbit Complement^c diluted 1:12 in Cytotoxicity Medium.
6. Incubate for 60 minutes at 37°C.
7. Place on ice.
8. Add Trypan Blue, 10% by volume of 1% Trypan Blue (w/v) added 3-5 minutes before scoring works well. Score live versus dead cells in a hemacytometer. Cytotoxic Index (C.I.) can be calculated as follows:

$$\text{C.I.} = 100 \times \frac{\% \text{ cyt (antibody + complement) } - \% \text{ cyt (complement alone)}}{100\% - \% \text{ cyt (complement alone)}}$$

Notes:

- a. Cedarlane Cytotoxicity Medium is RPMI-1640 with 25 mM Hepes buffer and 0.3% bovine serum albumin (BSA). BSA is substituted for the conventionally used fetal calf serum (FCS) because we have found that many batches of FCS contain complement dependent cytotoxins to mouse lymphocytes, thus increasing the background killing in the presence of complement. We recommend that cells not be exposed to FCS prior to or during exposure to antibody and complement. Some batches of BSA also contain complement dependent cytotoxins, resulting in the same problem. We screen for batches of BSA giving low background in the presence of complement and use the selected BSA for preparing Cedarlane Cytotoxicity Medium.
- b. Cedarlane Lympholyte[®]-M cell separation medium is density separation medium designed specifically for the isolation of viable mouse lymphocytes. This separation medium provides a high and non-selective recovery of viable mouse lymphocytes, removing red cells and dead cells. The density of this medium is 1.087 - 1.088. Isolation of mouse lymphocytes on cell separation medium of density 1.077 will result in high and selective loss of lymphocytes and should be avoided.

- c. Rabbit serum provides the most potent source of complement for use with antibodies to mouse cell surface antigens. However, rabbit serum itself is very toxic to mouse lymphocytes. Cedarlane Low-Tox[®]-M Rabbit Complement is absorbed to remove toxicity to mouse lymphocytes, while maintaining its high complement activity. When used in conjunction with Cedarlane Cytotoxicity Medium, this reagent provides a highly potent source of complement with minimal background toxicity.

Results:

Antibody Titration by Cytotoxicity Analysis:

Cell Source: Thymocytes

Donor: C3H/He


Cell Concentration: 1.1×10^6 cells/ml

Complement: Cedarlane Low-Tox[®]-M Rabbit Complement

Complement Concentration: 1:15

Procedure: Two-stage cytotoxicity as described on page 4

$$\text{C.I.} = 100 \times \frac{\% \text{ cyt (antibody + complement) } - \% \text{ cyt (complement alone)}}{100\% - \% \text{ cyt (complement alone)}}$$



Tissue Distribution by Cytotoxicity Analysis:

Procedure: see page 4

Antibody Concentration: 1:640

Strain: C3H/He

<u>Cell Source</u>	<u>C.I.</u>
Thymus	99
Spleen	28
Lymph Node	71

Strain Distribution by Cytotoxicity Analysis:

Procedure: see page 4

Antibody Concentration Used: 1: 500

Strains Tested: BALB/c, A.TH, CBA/J, C3H/He, C57BL/6

Positive: CBA/J, C3H/He

Negative: C57BL/6, BALB/c, A.TH

FUNCTIONAL ANALYSIS:

Method:

Cells were treated as described in “Cytotoxic Depletion of CD5 (Ly 1.2) Positive Lymphocytes” on page 7. Treated cells and controls were tested for:

- a) the ability to generate plaque-forming cells (PFC) using a modified Jerne haemolytic plaque assay
- b) the ability to generate cytotoxic T effector cells using a cytotoxic lymphocyte reaction (CTL) assay.

Cells were treated both before and after sensitization in the CTL assay. In vitro immunizations were used in all experiments.

Results:

Cell Source: Splenocytes

Donors: C57BL/6 and C3H/He

Cell Concentration: 1×10^7 cells/ml

Antibody Concentration used: 1:10

Complement: Cedarlane Low-Tox[®]-M Rabbit Complement

Complement Concentration: 1:10

Treatment of C3H/He splenocytes with anti-CD5 (Ly 1.1) plus complement was found to reduce the number of plaque-forming cells and inhibit cytotoxic T cell generation. Cytotoxic T effector cell function was not affected (cells treated after sensitization). No effect was observed when C57BL/6 cells were used. These results are consistent with the depletion of T helper cells of the Ly 1.1 phenotype.

CYTOTOXIC DEPLETION OF CD5 (Ly 1.1) POSITIVE LYMPHOCYTES:**Method:**

1. Prepare a cell suspension from the appropriate tissue in Cedarlane Cytotoxicity Medium or equivalent. Remove red cells and dead cells (where necessary) by purification of viable lymphocytes on Cedarlane Lympholyte[®]-M density cell separation medium. After washing, adjust the cell concentration to 1×10^7 cells per ml in Cytotoxicity Medium.
2. Add the antibody to a final concentration of 1:500 and mix. Alternatively, pellet the cells and resuspend in antibody diluted 1:500 in Cytotoxicity Medium.
3. Incubate for 60 minutes at 4°C.
4. Centrifuge to pellet the cells and discard the supernatant.
5. Resuspend to the original volume in Cedarlane Low-Tox[®]-M Rabbit Complement, diluted to the appropriate concentration in Cytotoxicity Medium. (Recommended concentration included with each batch of Low-Tox[®]-M Rabbit Complement.)
6. Incubate for 60 minutes at 37°C.
7. Monitor for percent cytotoxicity at this stage, before further processing. For this purpose remove a small sample from each tube, dilute 1:10 with medium, and add 1/10 volume of 1% Trypan Blue. After 3-5 minutes, score live versus dead cells in a hemacytometer.
8. For functional studies, remove the dead cells from the treated groups before further processing, particularly if the treated cells are to be cultured. This can be done by layering the cell suspension with separation medium and centrifuging at room temperature as per the instructions provided. Live cells will form a layer at the interface, while the dead cells pellet. The interface can then be collected and washed in Cytotoxicity Medium before being resuspended in the appropriate medium for further processing.

Alternatively, the cells can be washed and resuspended in the appropriate medium for further processing immediately after Step #6, provided that the dead cells will not interfere with subsequent assays.

FOR RESEARCH USE ONLY

® is a registered trademark of Cedarlane Laboratories Limited.

DF/06/21/00